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Tumor Microvasculature: Endothelial Leakiness 
and Endothelial Pore Size Distribution in a Breast 
Cancer Model
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Physics Department, Rensselaer Polytechnic Institute, Troy, NY 12180.
Abstract: Tumor endothelial leakiness is quantiﬁ  ed in a rat mammary adenocarcinoma model using dynamic contrast 
enhancement MRI and contrast agents of widely varying sizes. The contrast agents were constructed to be of globular 
conﬁ  guration and have their uptake rate into tumor interstitium be driven by the same diffusion process and limited only 
by the availability of endothelial pores of passable size. It was observed that the endothelial pore distribution has a steep 
power law dependence on size, r
−β, with an exponent of −4.1. The model of large pore dominance in tumor leakiness as 
reported in some earlier investigation with ﬂ  uorescent probes and optical chamber methods is rejected for this tumor model 
and a number of other tumor types including chemically induced tumors. This steep power law dependence on size is also 
consistent with observations on human breast cancer.
Keywords: dynamic contrast enhancement MRI, tumor endothelial leakiness, endothelial pore sizes, tumor 
microvasculature
Introduction
Tumor endothelial leakiness is well known and is associated with the processes of angiogenesis in 
growing tumors (1). The immature mircovasculature that is associated with angiogenesis has altered 
hemodynamic parameters: a high fractional vascular volume and permeability to a variety of contrast 
agents as demonstrated in clinical practice and the use of small molecular weight contrast agents or in 
preclinical studies with larger molecular weight contrast agents (2–5). The nature of this leakiness has 
not been well investigated. In particular, how does the permeability vary with probe size? Is the endo-
thelial leakiness dominated by large pores? These questions lead to the more fundamental ones of tumor 
biology: what is the pore size distribution in the endothelial junctions of tumors? Does the pore size 
distribution differ between benign and malignant tumors and can such differences be used to better 
design contrast agent probes for optimum discrimination?
Earlier investigations used ﬂ  uorescence methods in a tumor models gown in a special, dorsal-skin-
ﬂ  ap chamber that allowed for the application of ﬂ  uorescent microscopy to study probe leakage rates 
(6, 7). In one model, a human colon cancer xenograft implanted into this dorsal chamber in immuno-
deﬁ  cient mice, it was reported that variation of molecular probe size by a factor of approximately 2 
resulted only in a variation of permeability by about the same factor of 2 (6). Such a small factor results 
from the process of diffusion and its size dependence and not on any difference in pore number for the 
smaller size probes. This suggests that in these studies the tumor leakiness is dominated by large pores. 
In the large pore limit, differences in leak rates would be governed by differences in diffusion rates 
between particle agents. In this and a subsequent study, the large pore cutoff sizes were reported to be 
as large as 700nm (7).
These results do not agree with a variety of MRI observations for a variety of tumor xenografts in 
mice and rats and in chemically induced tumors in rats. Thus, there is a need for an explicit determination 
of tumor endothelial pore size distributions with methods other than used with the dorsal-skin-ﬂ  ap 
chamber system. The experimental design implemented in this study is straightforward. Some ﬁ  ve agents 
of globular structure ranging in size from approximately 2 to 7nm in radius were compared in rat mammary 
carcinoma models and DCE MRI was used to determine the probe permeability. A simple model is 
invoked to relate permeability dependence on probe size to endothelial pore size distribution.84
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Materials and Methods
Permeability measurements
The transport rate of a probe from the intravascular 
space to the tumor interstitium is at the center of 
these studies. A two compartment model has been 
used to describe the transfer of probes from the 
vascular to the extravascular space:
The quantitative expression for the observed 
signals in a two compartment model (8, 9) is 
derived from the expression for variation of agent 











where C0 and CT are the intravascular and the tumor 
extravascular concentration respectively, and k1 is 
the input transport rate into the tumor, in inverse 
time units, min
−1 and k2 is the rate of leaving the 
tumor, and γ is the clearance rate from the blood 
also in min
−1. The initial slope gives a good 
approximation of the input rate constant k1 since 
the second term is small for low tumor concentra-
tions. This is a matter of the kinetic rates in an 
actual experiment. Alternatively Eqn. 1 can be 
solved numerically to ﬁ  t the observed data and 
k1 can be derived explicitly even if the nonlinearity 
of the second term is substantially visible in the 
kinetic data.
The parameter of interest, permeability, or more 
precisely the permeability-surface area product, PS, 
is just the k1 rate constant put into appropriate units 
(µmoles/min*gm). Thus the usual parameter in 
dynamic contrast enhancement experiments, the PS 
term, the permeability-surface area product, is just
 PS  = k1 × 1000 µmoles/min*gm 
when C0 is in µmoles/ml and k1 is deduced from 
the rate of change of MRI signal in Eqn. 2 
below.
The task of measuring k1 is done by MR imag-
ing in a dynamic contrast enhancement method, 
DCE. The term CT(t) in Eqn. 1 is related to the 















The left hand side represents the observed 
fractional changes in signal intensity for an 
imaging voxel at time t as deﬁ  ned with S (t) the 
signal at time t, and S1 the signal immediately 
after injection, i.e. the blood volume signal, and 
S0 is the signal before contrast agent injection. 
CT (t) is the concentration of agent in the tumor 
at time t , the extravascular component, R1 is the 
proton longitudinal relaxivity of the agent , and 
T1 is the proton relaxation time of the tissue prior 
to agent injection (usually about 1 sec at a ﬁ  eld 
of 1.5T). The raw experimental data below are 
expressed as a dimensionless number, per cent 
enhancement per unit time, the left hand side of 
Eqn.2, per unit time, i.e. the observed slope of the 
fractional signal change of Eqn. 2 in the dynamic 
enhancement data set. The slope data can be 
compared directly since all the animal injections 
were at the same effective dose: actual dose 
corrected by relaxivity differences between the 
contrast agents used.
Dynamic contrast enhancement
A GE Signa 1.5T scanner was used for the animal 
imaging. The receive coil was a cylindrical 
solenoid coil, 5 cm diameter, into which the 
animals were placed under anesthesia (an 
intraperitoneal injection of a mixture of 
acepromazine, xylazine, ketamine, and atropine). 
A T1 spin echo sequence was used to generate the 
images: TE/TR 10/250 msec, Nex 2, 12 × 12 FOV, 
1mm slice thickness. An image was obtained prior 
to agent injection. At t = 0 the contrast polymeric 
agent was injected by tail vein at dose of 
0.025mmole Gd/kg. The ﬁ  rst image was obtained 
at t = 1 minute and subsequent images were 
obtained every 4 minutes for up to 40 minutes post 
injection.
To quantify tumor permeability, regions of 
interest, ROI regions encompassing the whole 
tumor were taken for 3 to 4 image slices of the 
tumor. A signal enhancement curve was obtained 
for each image slice as a function of time using a 
histogram method for the signal change values for 
each pixel. Since the tumor permeability responses 
were heterogeneous as is well known in the 
literature, we used the highest 10% of the 
responding pixels to deﬁ  ne the angiogenically 
active tumor permeability areas (2). Inclusion of 
all the pixels in a tumor slice results in a dilution 
of the average signal changes in such a slice by a 85
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large number of unresponding pixels, associated 
with presumably necrotic regions of the tumor. In 
previous reports, in order to avoid signal dilution 
and focus on the active tumor regions, the analysis 
regions were operator defined and usually 
encompassed the tumor rim (3,10–12). Unless 
otherwise specified the data below for tumor 
permeability are for the highest 10% of responding 
tumor pixels. Usually the high responding regions 
were in the periphery of the tumor as noted 
previously.
Permeability and pore sizes
The transport rate term k1 depends on pore size and 
pore number density in the following way for two 
cases. 1) Case of diffusion across capillary: The 
rate of transport across a pore (see for example 
ref. 13) is inversely proportional to the friction 
coefficient in the Einstein diffusion equation, 
D = kT/ f , and the friction coefﬁ  cient is propor-
tional to the hydrodynamic radius of the particle 
probe, the so called stokes radius. Therefore the 





1 ∝  (3)
where Np is the number of available pores for the 
probe in question. The transport rate must depend 
on all the pores that the probe can interrogate, 
i.e. all pores larger than the size of the particle 
probe. We can express this dependence in the fol-
lowing way:
  Nr d r pp
RH
=
∞ ∫ η ()  (4)
Here ηp(r) is the pore size distribution.
We now make a simple assumption that the pore 
size distribution is a power law distribution, i.e. 
ηp(r) = r
−β. This is a natural assumption as many 
phenomena in nature are described by such power 
law distributions and are connected to the fractal 
geometries often found in nature(see for example 
ref. 14). Furthermore, this assumption will be 
validated by the data itself and its agreement to a 
power law dependence. Integration of Eqn. 4 with 
ηp(r) = r
−β gives
  Nr pH =
−+ β 1
 
and Eqn. 3 becomes just
  kr H 1 ∝
−β (5)
The transport rate power law exponent is the expo-
nent of the pore size distribution.
Case 2) is convection as the driving force for 
transport. For this situation the transport rate can 
be written as
  kN p 1 ∝× Φ  (6)
where the term, Ф, encompases hydrostatic pres-
sure and other contributing terms to the ﬂ  uid ﬂ  ow 
through a set of pores. Because of convective ﬂ  ow, 
we have no explicit dependence on particle friction 
coefﬁ  cient. And if we keep Ф constant in the 
experimental design (same conditions for the 
animals, same anesthesia, same dosages etc.) 
variation in the observed transport rate k1 as a func-
tion of probe size can again be interpreted in terms 
of pore size distribution by repeating the integra-
tion steps shown above. In this case if the observed 
power law of the transport rate k1 has an exponent 
−β, then the pore distribution exponent would be 
(−β +1). In this case, variations in the Ф term would 
constitute the leading sources of variance in the 
transport measurements.
As will be shown below in describing the par-
ticle probes used, diffusion across small distances 
such as across a cell gap junction is very fast and 
diffusion in the MR measurement interval of 
4 minutes is large enough to encompass the mean 
capillary spacing in angiogenic regions of the 
tumor. Therefore, the diffusion model is clearly 
applicable to these probes and Eqn. 5 for the pore 
distribution is a valid interpretation of the experi-
mental observations shown in Figure 2.
Contrast agent probes
1) Synthesis of Gd-DTPA-polylysine in globular 
collapsed state.
Polylysine was purchased from Sigma-Aldrich 
(degree of polymerization by viscosity was 455 
and 613 for two different lots used). A mixed 
anhydride method was used to couple, diethylene-
triaminepentaacetic acid, DTPA (Sigma-Aldrich, 
98% pure) to the polylysine with modiﬁ  cations 
from the published protocol (15). DTPA 86
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(7 equivalents to 1 of lysine) was placed in dry 
acetonitrile and tryethylamine (5 equivalents to 1 
of DTPA) was added and warmed with stirring 
until the solution was clear. It was then placed 
under a N2 atmosphere in a −30 °C bath. Isobu-
tylchloroformate, IBCF, was then added slowly 
and the solution was allowed to mix for 30 min-
utes. The resulting mixture was then added drop-
wise to a solution of polylysine (in 100mM sodium 
bicarbonate) in an ice bath with stirring over 
5 minutes. The solution was allowed to come to 
room temperature and was stirred for 16 hours. 
The solution was then placed in a rotary evapora-
tor to eliminate the volatile organic components 
and then further puriﬁ  ed through diaﬁ  ltration 
(Amicon 8400 stirred ﬁ  ltration cell, 30,000 Mw 
cutoff filters). The purified product was then 
labeled with Gd through addition of Gd-Na citrate 
until no free Gd was detected in a colorimetric 
assay (10 µL of solution added to 1 mL of 1µM 
of Arsenazo III). Free lysines were determined 
with a trinitrobenzensulfonic acid, TNBS, colori-
metric assay (16) calibrated with monomeric 
lysine, lysine containing peptides, and N-acetyl-
lysine. This synthesis protocol resulted in variable 
conjugation levels of DTPA for different synthesis 
runs, ranging from 60% to 95%. Increasing the 
temperature of the ICBF bath to −20 °C and run-
ning the coupling reaction for a shorter period, 
6 hours, resulted in even lower conjugation levels. 
These products were later characterized with 
relaxivity measurements after Gd labeling. Gd 
content in all the labeled products was determined 
by ICP-AES.
For purposes of these experiments, only two of 
the lower conjugation constructs were used that 
were veriﬁ  ed to have a collapsed conformation by 
size exclusion chromatography and dynamic light 
scattering measurements of hydrodynamic size. For 
more details on Gd-DTPA-polylysine conformation 
see previously publisher reports (17,18).
2) Synthesis of Gd-DTPA-albumin and Gd-
DTPA-IgG
An identical protocol was followed as above. In 
the coupling reaction, the mixed anhydride slurry 
was added to a solution of either bovine serum 
albumin or IgG (Sigma-Aldrich, 100mg in 12 mL 
100 mM sodium bicarbonate). Coupling proceeded 
for 16 hours and then the same puriﬁ  cation proce-
dures were undertaken as for the polylysine. Gd 
content was determined by ICP-AES.
3) Use of Gad 17 data relative to Gd-DTPA-albumin
Gad 17 is a dendrimeric polymer agent whose 
hydrodynamic size (mean of two values given in 
the literature, radius of 2 nm +/−0.2 nm ) extends 
the size range of our present investigation (limited 
from 3.5nm for albumin to 6.5nm for the IgG con-
structs) to allow a more meaningful power law 
range ﬁ  t. A detailed study on the kinetics of Gad 17 
and Gd-albumin in a rat mammary adenocarcinoma 
model was reported (10). The permeability of Gad 
17 was found to be 12 times higher than for Gd-
albumin for the tumor periphery, corresponding to 
the high 10% of responding pixels: PS = 10.3 µl/ 
min*cc and 0.83 µl/min*cc respectively. I use this 
multiplying factor of 12 for our observed 
Gd-albumin slope to fold the Gad 17 permeability 
into our data set of uptake slope vs. probe hydro-
dynamic radius. I note that the baseline Gd-albumin 
permeability values for the two rat mammary 
adenocarcinoma models were similar, 0.83 vs. 1.6 
µl/min*cc, and no further adjustments in projected 
uptake slope for a Gad 17 size probe was made.
Hydrodynamic sizes
The hydrodynamic size of the constructs used was 
determined by dynamic light scattering methods. 
The value for Gd-DTPA-albumin matched litera-
ture values and was found to be 3.5 +/−0.2 nm.
Probe diffusion
From the hydrodynamic sizes it is straightforward 
to calculate the diffusion coefficients of these 
probes given the well determined value for albumin. 
We ﬁ  nd then, that for water and 37 ºC, that the dif-
fusion coefﬁ  cients are: 1.4 × 10
−6 for Gad 17, the 
smallest probe, 8.1 × 10
−7, for albumin, and 
4.4 × 10
−7 for IgG the largest(in units of cm
2/sec). 
To cross a cell gap junction of say 2 µm, the time 
required using the standard diffusion equation, 
x
2 = 2Dt, is 0.014, 0.024, and 0.045sec respectively. 
And in a MR measurement time interval of 
4 minutes, the diffusion distances are 259, 197, and 
145 µm respectively. These distances easily encom-
pass the mean capillary spacing of angiogenic 
tissue, some 100 µm, (from a blood volume fraction 
of 4% and mean capillary diameter of 20 µm).
Polymer conformation
The two Gd-DTPA-polylysine polymers used in 
these experiments were analyzed for polymer 
conformation by size exclusion chromatography as 87
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previously described (21,22). The two constructs in 
the present experiments eluted at the times predicted 
for a collapsed globular conformation matching the 
behavior of protein standards in the same molecular 
size range. A coiled polymer in a collapsed globular 
conformation elutes at a much later time for the same 
monomer number than one in an extended confor-
mation. It was important that only globular con-
structs be used for the pore distribution experiments 
because the extended- linear polymer constructs are 
known to translocate through the tumor endothelium 
by a different process, that of polymer reptation (17, 
19), than the particle-like probes which extravasate 
by diffusion/ convection through available openings 
in the endothelium.
Animal model
A rat mammary adenocarcinoma cell line, Mat B3 
-13762, ATCC – CRL 1666, was used to implant 
into female Fisher 344 rats. Subcutaneous tumors 
were grown by implanting 2 × 10
6 cells in 0.2ml 
Hank’s balanced salt solution beneath the dorsal 
skin ﬂ  ap while the animal was anesthesized. After 
about 8–10 days the tumors reached a size of 
between 5 and 10 mm in diameter and the imag-
ing experiments then commenced. Tumors larger 
than about 15mm in diameter were not used in 
these studies as the presence of extensive necrotic 
regions complicated the goal of assessing the 
active angiogenic tumor permeability and tumor 
blood volume in the viable regions of the 
tumor.
All animal experiments were conducted in 
accordance with the approval of Institutional 
Animal Care and Use Committee and followed the 
New York State Health Department regulations.
Proton relaxivity
The longitudinal proton relaxivity of the various 
molecular constructs was measured at a ﬁ  eld of 
1.5T and 25 ºC by standard methods (12).
Results and Discussion
For proper normalization of dose, so that the 
observed signal slopes could be directly compared 
between agents used, the R1 values of the 
constructs were measured and the doses were 
adjusted relative to Gd-DTPA-albumin construct 
(R1 = 15 +/−0.5 mM
−1 sec
−1). The relaxivity of the 
two collapsed polymer constructs were 11.5 and 
10.5 mM
−1 sec
−1 with 40 and 20% free lysines 




The hydrodynamic radii of the albumin and 
the IgG constructs were 3.5 +/−0.2 nm and 
6.5 +/−1.0 nm, and the two collapsed polylysine 
constructs were 3.7 +/−0.3 and 5.3 +/−0.3 nm in 
hydrodynamic radius. The differences in polylysine 
sizes was driven largely by degree of intramolecu-
lar ionic bonding—the construct with the higher 
free lysine content had a smaller size as expected 
from molecular modeling calculations (17).
In a related study of breast cancer hemodynam-
ics, DCE data were taken on a xenograft of human 
breast cancer, MCF7, in immunodeﬁ  cient mice. 
This data for Gd-DTPA-albumin probes for MCF-7 
could be compared directly with the literature (2). 
The vascular volume fraction and the PS permeabil-
ity values for the highest 10% of responding pixels 
were found to be 31 +/−3 µl/gm and 0.9 +/−0.4 
µl/min*gm and compare to 33 +/−5 µl/gm and 
1.5 +/−0.3 µl/min*gm found in the Bhujwalla 
laboratory (2). The results are in agreement for the 
vascular volume fraction but differ somewhat for 
the permeability. This difference could be due to 
the sensitivity of transport to experimental factors 
and errors or to orthotopic (Bhujwalla laboratory) 
vs. subcutaneous (this work) implantation of 
tumors. The former may be more likely as differ-
ences of factor of 2 in permeability were observed 
for subcutaneous Mat lylu tumors (results from this 
laboratory compared to results from ref. 2, also 
subcutaneous) and as mentioned above differences 
for rat mammary adenocarcinoma between ref. 10 
and results of this laboratory. However, such 
variation does not materially effect the conclusions 
regarding transport rate power law steepness shown 
in Figure 2 as those rate changes encompass 
changes of several orders of magnitude.
Raw DCE data are shown in Figure 1 for albu-
min and IgG probes for the rat mammary adeno-
carcinoma model. There is a large difference in 
signal slope for the two probes of 3.5 and 6.5 nm 
hydrodynamic radii respectively.
All of the slope data, including the extrapolated 
value for the 2 nm radius probe that is derived from 
an earlier study on a rat adenocarcinoma model, 
are shown in Fig. 2. The data show a very steep 
drop in the transport rate, i.e., the initial slope of 
the DCE signals vs. time, as a function of probe 
size. The power law ﬁ  t has an exponent of −4.1 
with a R
2 value of 0.989. This exponent of −4.1 88
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+/−0.3 is therefore the  exponent of the pore size 
distribution for diffusion transport. The power law 
is tested over the range of sizes from 2 to 6.5 nm 
in radius and over this range, the transport rate is 
seen to vary by two orders of magnitude, a steep 
dependence indeed.
Comparisons with other MRI 
observations
Conﬁ  rming a steep pore distribution was the 
study of Walker 256 sarcoma in rats (4) in which 
there was a 13 fold change in uptake rate when 
Gad 17, a 30kD dendrimer construct (2nm radius) 
was compared to Gd-DTPA-polylysine (a con-
struct of polymerization number 70, 50kD, and 
a computed radius of ∼3.4 nm radius from mea-
surements of Gd-polylysine constructs of various 
degrees of polymerization, form 100 to 800, and 
the corresponding dynamic light scattering mea-
surements of hydrodynamic radius, data not 
shown). An even larger difference in uptake slope 
between these agents, >13, was observed for rat 
mammary adenocarcinoma R3230. Thus probe 
size changes of about a factor of 1.7 results in a 
change of uptake rate by a factor of 13 and even 
greater than 13 in the two rat tumor models (con-
sistent with a power law exponent for transport 
rate of −4.8.
I have already remarked on the comparison of 
Gd-albumin with Gad 17 in a rat mammary adeno-
carcinoma model (10). A factor of 12 in the PS 
value was observed between Gad 17 (2 nm) and 
Gd-albumin (3.5 nm )which is consistent with a 
power law exponent of −4.5.
Yet another example of a steep dependence on 
probe size can be found in the study of chemically 
induced tumors in rats (11). The permeability of 
the induced malignant tumors showed a steep 
dependence on probe size when an albumin agent 
was compared to a rapid clearance 6.7kD agent 
P792—a construct that has a disc structure of 
approximately 3nm radius and ∼ 1.2 nm half 
width (20).
Interestingly in this study, the benign tumors were 
not leaky to the albumin agent, PS = 0 +/−0.01 
µl/ min*gm, whereas the smaller P792 construct 
showed no signiﬁ  cant difference in PS values 
between malignant and benign tumors. The role of 
pore size distribution in benign vs. malignant may 
therefore be an interesting question of tumor biol-
ogy and also an important factor for discriminating 
between the tumor types.
Connection to other tumor models
How general is this rule for pore sizes? Using this 
pore size distribution model we can go further and 
compare to several very different studies involving 
relatively large probes. In one, iron oxide particles, 
Clariscan particles, of ∼5.5 to 6 nm radius, were 
used in DCE measurements of human breast 
tumors (21). The DCE curve, enhancement vs. 
time, given for an active tumor, could be used to 
deduce k1 quantitatively and the value is within a 












































Figure 1. DCE data for two contrast agents Gd-albumin(upper data set) and Gd-IgG (lower data set) for identical effective dose of 
0.025 mmole Gd/kG. The fractional signal change is as deﬁ  ned in Eqn. 2 and is for the highest 10% of the responding image pixels. The 
slope of this fractional change is indicated by the solid lines and is proportional to the uptake rate of the agent into the tumor, i.e., the PS, 
permeability-surface area product for the agent.89
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scaling behavior shown in Figure 2 for rat mam-
mary adenocarcinoma tumor models.
In another study, a MPEG agent, a large polymer 
construct, was used in a rat mammary carcinoma 
model and its uptake rate into tumors was deter-
mined by radiolabeling and tumor concentration 
measurements at a number of time points over 24 
hours (22). The deduced k1 rate from the reported 
agent concentration data and the projected rate for 
this agent (given its size from molecular weight 
determinations) are within a factor of 2 of each 
other.
Also, using the data for radiolabeled MION -Tf 
particles and the tissue activity for tumors with 
transferrin receptors after a ﬁ  xed period (23), it is 
possible to estimate the k1 rate given the blood cir-
culation time and the size of the particles. And if the 
size of these particles is as stated, i.e. to be equiva-
lent to 770kD proteins (24), than the k1 rate that is 
projected from the power law scaling agrees with 
the observed tissue values in this experiment.
We see then, that for a variety of tumors, includ-
ing human breast cancer and for varying particle 
formulations, and with MR imaging as well as with 
radiolabel methods , the steep pore size scaling 
demonstrated in Figure 2, holds true in a general 
way. Transport rate projections through the use of 
this quantitative model and these other observations 
of tumor uptake agree in one case and differ by a 
factor of 2 in other cases—within errors of the 
model prediction as shown in the semilog plot of 
Figure 2 (note that a factor of 2 is 0.3 units of the 
log scale). This agreement suggests that even for 
differing experimental conditions and tumor types 
the general trend of Figure 2 seems to hold.
Conclusions
A steep power law, kr H 1 ∝
−β , for the forward tran-
sendothelial transport rate as function of probe 
size was observed for a rat mammary adenocar-
cinoma model. As a consequence, the tumor 
endothelial pore size distribution has a steep 
dependence also with an exponent of −4.1 for 
transport by diffusion (and −3.1 for transport by 
convection alone). This steep distribution appears 
Figure 2. Fractional signal slope, as in Figure 1, plotted as function of contrast agent hydrodynamic radius for rat mammary adenocarcinoma 
tumors. Data points on right, this work(The number of animals for each experimental point form left to right, are 7, 3, 3, and 3). Upper left 
data point, extrapolated to present slope values from PS values given relative to albumin (ref. 10) as detailed in text. Power law ﬁ  t over this 
range of sizes gives an exponent of −4.1 with R2 of 0.989.90
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to hold for a number of other tumor models and 
includes chemically induced tumors in rats. 
Further reports in the literature on yet other tumor 
models appear also to be consistent with this 
quantitative power law dependence of transport 
rate on probe size and include comparisons to 
human breast cancer uptake rates with small iron 
oxide particle agents.
There was no evidence for large pore dominance 
in any of these tumor models. From reports using 
two different size contrast agents, there is evidence 
that benign and malignant tumors may have dif-
ferent endothelial pore size distributions. Present 
clinical contrast agents, being of small molecular 
size, may not be ideal for capturing these differ-
ences and a better understanding of tumor endo-
thelial pore size distributions may lead to improved 
contrast agents or more effective therapeutic con-
structs.
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